DocGo Inc. Form 8-K Summary
Business Context and Reporting Period
DocGo Inc. filed this Form 8-K on March 8, 2024, reporting events occurring on March 7, 2024. The filing concerns changes to the board of directors and a separation and consulting agreement with former Chair Stan Vashovsky.
Board and Management Changes
- Stan Vashovsky will retire as a director and Chair of the Board effective March 31, 2024.
- Lee Bienstock, DocGo’s Chief Executive Officer, was appointed as a Class I director effective April 1, 2024.
- Steven Katz, currently a director, Chair of the Audit and Compliance Committee, and Lead Independent Director, will become Chair of the Board effective April 1, 2024.
- Mr. Vashovsky stated that his departure was motivated by family and personal pursuits and was not due to any disagreement with the Company regarding operations, disclosures, policies, or practices.
Financial Metrics, Liquidity, and Compensation
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics.
Under a separation and consulting agreement dated March 7, 2024, Mr. Vashovsky will provide consulting and relationship-support services through March 31, 2025. He will receive a quarterly equity grant with an approximate grant-date fair value of $35,000 during the consulting period and will be eligible for Company-subsidized healthcare coverage in exchange for a release of claims.
Outlook, Risks, and Unusual Items
- The filing provides no financial guidance or business outlook.
- Mr. Vashovsky may advise executive officers and the Board and assist with existing customer and investor relationships.
- The consulting agreement includes restrictive covenants; the filing states that the agreement’s summary is qualified by the complete agreement filed as Exhibit 10.1.
- The Company reported no related-party transactions requiring disclosure under Item 404(a) with respect to Mr. Bienstock’s board appointment.
Important Facts for Investors to Verify
- Effective dates: Mr. Vashovsky’s departure on March 31, 2024, and the appointments of Mr. Bienstock and Mr. Katz on April 1, 2024.
- The full separation and consulting agreement filed as Exhibit 10.1, including equity grant terms, healthcare benefits, release provisions, and restrictive covenants.
- The potential aggregate cost and accounting treatment of quarterly equity grants through March 31, 2025.
- Any subsequent filings describing changes to board committees, governance responsibilities, or the consulting arrangement.